GlassScriptPhysician profile
Michael D Lehrer
NPI 1578919403
$15,086.22
in general payments reported to CMS, 2019-2025
34 companies · $5,162 in 2025
The $5,162 reported for 2025 was more than what 90% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $766 · 2020: $438 · 2021: $2,222 · 2022: $2,141 · 2023: $2,004 · 2024: $2,352 · 2025: $5,162.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,183 · Consulting Fee: $2,040 · Education: $295.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,183.28 |
| Consulting Fee | $2,040.00 |
| Education | $294.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $2,707.76 | 2022-2025 | Opzelura |
| Abbvie INC. | $1,569.56 | 2020-2025 | |
| Janssen Biotech, INC. | $1,514.74 | 2020-2025 | Tremfya, Simponi Aria, Stelara |
| Regeneron Healthcare Solutions, INC. | $1,462.51 | 2020-2025 | Dupixent, Libtayo |
| Sun Pharmaceutical Industries INC. | $1,342.58 | 2020-2025 | Absorica Ld, Winlevi, Blu-U |
| Leo Pharma INC. | $812.81 | 2020-2025 | Adbry |
| Pfizer INC. | $667.77 | 2020-2025 | |
| Novartis Pharmaceuticals Corporation | $623.16 | 2020-2025 | |
| Ucb, INC. | $506.38 | 2021-2025 | Bimzelx, Cimzia |
| Amgen INC. | $384.86 | 2021-2025 | Otezla, Otezla |
| Galderma Laboratories, L.P. | $370.95 | 2021-2025 | Nemluvio |
| Genzyme Corporation | $323.35 | 2019-2024 | |
| Lilly USA, LLC | $321.97 | 2021-2025 | Taltz, Olumiant, Ebglyss |
| Celgene Corporation | $274.67 | 2019 | |
| Allergan, INC. | $257.81 | 2019 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $251.44 | 2020-2024 | Jublia |
| Arcutis Biotherapeutics, INC. | $244.54 | 2023-2025 | Zoryve |
| Almirall LLC | $237.58 | 2021-2025 | Klisyri, Seysara |
| E.R. Squibb & Sons, L.L.C. | $195.33 | 2022-2025 | Sotyktu |
| Vyne Pharmaceuticals INC. | $173.61 | 2020-2021 | |
| Mayne Pharma Commercial LLC | $156.09 | 2020-2025 | |
| Merz North America, INC. | $133.36 | 2022-2025 | |
| Janssen Scientific Affairs, LLC | $109.32 | 2019 | |
| Surgenex LLC | $95.61 | 2025 | Ardeograft, Pellograft, Surmatrix |
| Biowound Solutions, INC. | $74.83 | 2024-2025 | Bio-Connekt |
| Journey Medical Corporation | $56.17 | 2025 | |
| Organogenesis INC. | $41.89 | 2025 | Puraply Wound Matrix, Nushield |
| Verrica Pharmaceuticals INC. | $40.37 | 2023-2024 | Ycanth |
| Nabriva Therapeutics, Plc | $27.30 | 2021-2022 | |
| Biofrontera INC. | $26.22 | 2021 | |
| Lnhc, INC | $24.58 | 2025 | Zelsuvmi |
| Epi Health, LLC | $23.35 | 2021 | |
| Blueprint Medicines Corporation | $18.71 | 2023 | |
| Encore Dermatology INC. | $15.04 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Lehrer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.